Skip to main content
Top
Published in: Tumor Biology 10/2016

01-10-2016 | Original Article

Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease

Authors: Irena Marjanovic, Jelena Kostic, Bojana Stanic, Nadja Pejanovic, Bojana Lucic, Teodora Karan-Djurasevic, Dragana Janic, Lidija Dokmanovic, Srdja Jankovic, Nada Suvajdzic Vukovic, Dragica Tomin, Ognjen Perisic, Goran Rakocevic, Milos Popovic, Sonja Pavlovic, Natasa Tosic

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

The age-specific differences in the genetic mechanisms of myeloid leukemogenesis have been observed and studied previously. However, NGS technology has provided a possibility to obtain a large amount of mutation data. We analyzed DNA samples from 20 childhood (cAML) and 20 adult AML (aAML) patients, using NGS targeted sequencing. The average coverage of high-quality sequences was 2981 × per amplicon. A total of 412 (207 cAML, 205 aAML) variants in the coding regions were detected; out of which, only 122 (62 cAML and 60 aAML) were potentially protein-changing. Our results confirmed that AML contains small number of genetic alterations (median 3 mutations/patient in both groups). The prevalence of the most frequent single gene AML associated mutations differed in cAML and aAML patient cohorts: IDH1 (0 % cAML, 5 % aAML), IDH2 (0 % cAML, 10 % aAML), NPM1 (10 % cAML, 35 % aAML). Additionally, potentially protein-changing variants were found in tyrosine kinase genes or genes encoding tyrosine kinase associated proteins (JAK3, ABL1, GNAQ, and EGFR) in cAML, while among aAML, the prevalence is directed towards variants in the methylation and histone modifying genes (IDH1, IDH2, and SMARCB1). Besides uniform genomic profile of AML, specific genetic characteristic was exclusively detected in cAML and aAML.
Appendix
Available only for authorised users
Literature
2.
go back to reference Weinstein HJ. Acute myeloid leukemia. In: Pui CH, editor. Childhood Leukemias. Cambridge: Cambridge University Press; 1999. p. 322–35. Weinstein HJ. Acute myeloid leukemia. In: Pui CH, editor. Childhood Leukemias. Cambridge: Cambridge University Press; 1999. p. 322–35.
3.
5.
go back to reference Krstovski N, Tosic N, Janic D, Dokmanovic L, Kuzmanovic M, Spasovski V, et al. Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature. Med Oncol. 2010;27:640–5. doi:10.1007/s12032-009-9261-5.CrossRefPubMed Krstovski N, Tosic N, Janic D, Dokmanovic L, Kuzmanovic M, Spasovski V, et al. Incidence of FLT3 and nucleophosmin gene mutations in childhood acute myeloid leukemia: Serbian experience and the review of the literature. Med Oncol. 2010;27:640–5. doi:10.​1007/​s12032-009-9261-5.CrossRefPubMed
11.
12.
go back to reference Oki K, Takita J, Hiwatari M, Nishimura R, Sanada M, Okubo J, Adachi M, Sotomatsu M, Kikuchi A, Igarashi T, Hayashi Y, Ogawa S. IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies. Leukemia. 2011;25:382–4.CrossRefPubMed Oki K, Takita J, Hiwatari M, Nishimura R, Sanada M, Okubo J, Adachi M, Sotomatsu M, Kikuchi A, Igarashi T, Hayashi Y, Ogawa S. IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies. Leukemia. 2011;25:382–4.CrossRefPubMed
13.
go back to reference Andersson AK, Miller DW, Lynch JA, Lemoff AS, Cai Z, Pounds SB, Radtke I, Yan B, Schuetz JD, Rubnitz JE, Ribeiro RC. IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia. 2011;25:1570–7.CrossRefPubMed Andersson AK, Miller DW, Lynch JA, Lemoff AS, Cai Z, Pounds SB, Radtke I, Yan B, Schuetz JD, Rubnitz JE, Ribeiro RC. IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia. 2011;25:1570–7.CrossRefPubMed
23.
go back to reference Kuzmanovic M, Tosic N, Colovic N, Karan-Djurasevic T, Spasovski V, Radmilovic M, et al. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia. Acta Haematol. 2012;128:203–12. doi:10.1159/000339506.CrossRefPubMed Kuzmanovic M, Tosic N, Colovic N, Karan-Djurasevic T, Spasovski V, Radmilovic M, et al. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia. Acta Haematol. 2012;128:203–12. doi:10.​1159/​000339506.CrossRefPubMed
28.
go back to reference Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014;28:1586–95. doi:10.1038/leu.2014.55.CrossRefPubMed Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia. 2014;28:1586–95. doi:10.​1038/​leu.​2014.​55.CrossRefPubMed
32.
go back to reference Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol. 2010;21:1179–88. doi:10.1093/annonc/mdp452.CrossRefPubMed Kim DH, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol. 2010;21:1179–88. doi:10.​1093/​annonc/​mdp452.CrossRefPubMed
33.
go back to reference Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015;28:706–14. doi:10.1038/modpathol.2014.160.CrossRefPubMed Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, et al. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol. 2015;28:706–14. doi:10.​1038/​modpathol.​2014.​160.CrossRefPubMed
34.
Metadata
Title
Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease
Authors
Irena Marjanovic
Jelena Kostic
Bojana Stanic
Nadja Pejanovic
Bojana Lucic
Teodora Karan-Djurasevic
Dragana Janic
Lidija Dokmanovic
Srdja Jankovic
Nada Suvajdzic Vukovic
Dragica Tomin
Ognjen Perisic
Goran Rakocevic
Milos Popovic
Sonja Pavlovic
Natasa Tosic
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5142-7

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine